Thermo-Reversible Ocular Hydrogel for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease lack effective and convenient formulations that can utilize hydrogels as active ingredients, with existing formulations relying solely on hydrogels as carriers for external active ingredients, and there is a need for novel methods to treat dry eye disease.
Innovation Solution
A pharmaceutical composition comprising a reversely thermo-reversible hydrogel as the active ingredient, composed of a water-soluble block copolymer and associative gelling agent, which forms a gel at body temperature, allowing for convenient liquid application and gelling in the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy or radiotherapy is used to treat cancer, then tumor cells can be killed, but normal healthy cells are also damaged and the disease progresses
Solution Approach 1:
The invention segments the treatment approach by using specific oligonucleotide sequences that selectively bind to and inhibit only cancer-related genes (such as Bcl-2, Bcl-xL, Mcl-1, and IAP genes) while leaving normal cellular functions intact. This gene-specific targeting divides the therapeutic action into precise molecular interventions rather than broad-spectrum attacks on all dividing cells.
Solution Approach 2:
The patent introduces oligonucleotide molecules as intermediary agents that mediate between the treatment goal and the target genes. These oligonucleotides act as selective mediators that bind to specific mRNA sequences of cancer-promoting genes, blocking their function without directly damaging cellular structures or healthy tissue.
2Productivity
If high doses of chemotherapy or radiotherapy are administered to kill more tumor cells, then cancer progression is slowed, but side effects increase and patient quality of life deteriorates
Solution Approach 1:
The treatment applies local quality by delivering therapeutic action specifically to cancer-related molecular targets rather than uniformly affecting all cells. The oligonucleotides are designed with sequence specificity that ensures they only bind to and inhibit cancer-promoting genes, creating a localized therapeutic effect at the molecular level while sparing normal cellular processes.
Solution Approach 2:
The invention changes the fundamental parameter of treatment specificity by using nucleic acid sequence complementarity as the selection criterion. Instead of relying on cell permeability or metabolic activity parameters that affect all cells, the treatment uses specific base-pairing parameters to distinguish cancer genes from normal genes, enabling selective inhibition without dose escalation.
3Reliability
If traditional cancer treatments are used, then some tumor cells are eliminated, but the treatments are expensive and require extensive hospitalization
Solution Approach 1:
The oligonucleotide treatment exhibits self-service characteristics by relying on the natural cellular machinery for its action. The oligonucleotides enter cells and utilize the cell's own transcription and translation systems to achieve gene inhibition, requiring no complex external delivery mechanisms or intensive medical intervention beyond administration.
Solution Approach 2:
The patent replaces mechanical and physical treatment methods (such as surgery, radiation, and chemotherapy) with a molecular biochemical mechanism. Instead of using external forces or toxic chemicals that require complex delivery systems and monitoring, the treatment uses specific nucleic acid binding and RNA interference mechanisms that occur naturally within the cell's biochemical environment.
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a pharmaceutical composition comprising a reversely thermo-reversible hydrogel as active ingredient, for administration to the eye of mammalian subjects. In particular, it relates to a pharmaceutical composition for use in, and a method for, the ophthalmic treatment of dry eye disease.